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Abstract
Background: The goal of this study was to estimate the distribution of udder pathogens and their antibiotic
resistance in Estonia during the years 2007-2009.
Methods: The bacteriological findings reported in this study originate from quarter milk samples collected from
cows on Estonian dairy farms that had clinical or subclinical mastitis. The samples were submitted by local
veterinarians to the Estonian Veterinary and Food Laboratory during 2007-2009. Milk samples were examined by
conventional bacteriology. In vitro antimicrobial susceptibility testing was performed with the disc diffusion test.
Logistic regression with a random herd effect to control for clustering was used for statistical analysis.
Results: During the study period, 3058 clinical mastitis samples from 190 farms and 5146 subclinical mastitis
samples from 274 farms were investigated. Positive results were found in 57% of the samples (4680 out of 8204),
and the proportion did not differ according to year (p > 0.05). The proportion of bacteriologically negative samples
was 22.3% and that of mixed growth was 20.6%. Streptococcus uberis (Str. uberis) was the bacterium isolated most
frequently (18.4%) from cases of clinical mastitis, followed by Escherichia coli (E. coli) (15.9%) and Streptococcus
agalactiae (Str. agalactiae) (11.9%). The bacteria that caused subclinical mastitis were mainly Staphylococcus aureus
(S. aureus) (20%) and coagulase-negative staphylococci (CNS) (15.4%). The probability of isolating S. aureus from
milk samples was significantly higher on farms that had fewer than 30 cows, when compared with farms that had
more than 100 cows (p < 0.005). A significantly higher risk of Str. agalactiae infection was found on farms with
more than 600 cows (p = 0.034) compared with smaller farms. The proportion of S. aureus and CNS isolates that
were resistant to penicillin was 61.4% and 38.5%, respectively. Among the E. coli isolates, ampicillin, streptomycin
and tetracycline resistance were observed in 24.3%, 15.6% and 13.5%, respectively.
Conclusions: This study showed that the main pathogens associated with clinical mastitis were Str. uberis and
E. coli. Subclinical mastitis was caused mainly by S. aureus and CNS. The number of S. aureus and Str. agalactiae
isolates depended on herd size. Antimicrobial resistance was highly prevalent, especially penicillin resistance in
S. aureus and CNS.
Background
Bovine mastitis is the most common disease in dairy cows
worldwide, and antimicrobial therapy is the primary tool
for the treatment of mastitis. The prevalence of mastitis
pathogens and their antimicrobial resistance have been
investigated in numerous studies around the world. The
main pathogens that cause subclinical mastitis are coagu-
lase-negative staphylococci (CNS), Corynebacterium bovis
(C. bovis) and Staphylococcus aureus (S. aureus) [1-5].
Coliforms, Streptococcus uberis (Str. uberis) and S. aureus
are the pathogens isolated most frequently from clinical
mastitis samples [6-8]. Streptococcus agalactiae (Str. aga-
lactiae) has been largely eradicated from herds in Europe
[3], but in studies from the United States, 7.7% and 13.1%
of samples contained Str. agalactiae [9,10].
Several methods, such as disc diffusion, agar dilution,
broth dilution and broth microdilution are suitable for
in vitro antimicrobial susceptibility testing. Depending
on the study design and the methodology used, the anti-
microbial susceptibility of udder pathogens varies greatly
between studies. For example, studies from France and
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the UK have reported a high prevalence of penicillin-
resistant S. aureus (36.2%, 56%) [11,12], whereas a low
percentage of resistant isolates (4-9%) were found in the
Netherlands and Norway [13,14]. The streptococci that
cause mastitis are susceptible to b-lactam antibiotics;
however, resistance to macrolides and lincosamides is
notable [13,15]. In vitro resistance of E. coli to different
antimicrobials has been reported to be low [13,14,16,17].
National studies of mastitis prevalence provide impor-
tant information through the monitoring of national
udder health status, and they enable national guidelines
to be developed for the prudent use of antibiotics in
each country [18]. During recent decades, only broad-
spectrum antibiotics have been used for the treatment
of clinical mastitis in Estonia. For example, in the years
2006-2009, 15 different combinations of antibiotics were
available for use in 18 intramammary preparations that
were authorised by the Estonian State Medical Agency
[19]. Given that a large overview of udder pathogens
and their antibiotic resistance has not been performed
in Estonia, the goal of this study was to estimate the dis-
tribution of udder pathogens and their antibiotic resis-
tance during the years 2007-2009 in Estonia.
Methods
Sample collection
Milk samples were submitted to the Estonian Veterinary
and Food Laboratory during the period 2007-2009. Quar-
ter milk samples were collected from cows on Estonian
dairy farms by local veterinarians or farmers. Clinical mas-
titis was diagnosed when visible abnormalities of udder
(swelling) were detected or milk from a quarter had
abnormal viscosity (watery, thicker than normal), colour
(yellow, blood-tinged) or consistency (flakes or clots) [20].
Normal milk appearance, together with a positive Califor-
nia Mastitis Test result (score greater than 1), was used to
make a diagnosis of subclinical mastitis.
The samples were sent to the laboratory either for iso-
lation of the clinical mastitis pathogen and determina-
tion of its antimicrobial susceptibility or to determine
the reason for an increased somatic cell count.
Laboratory analysis
Bacterial species were identified using accredited metho-
dology based on the National Mastitis Council [21] stan-
dards. From each sample, 0.01 ml of milk was cultured
on blood-esculin agar and incubated for 48 h at 37°C.
The plates were examined after 24 and 48 h of incuba-
tion. A minimum of five colonies of the same type of
bacterium was recorded as bacteriologically positive, and
growth of more than two types of bacterial colonies was
categorised as mixed growth. No bacterial growth was
recorded when fewer than five colony-forming units
were detected during 48 h of incubation.
Once they had been isolated and identified, pure cul-
tures of udder pathogens were tested for antibacterial
susceptibility with the disc diffusion assay on Mueller-
Hinton agar. Testing was performed according to the
recommendation of the Clinical and Laboratory Stan-
dards Institute (CLSI) document M31-A2 in the years
2007-2008 and M31-A3 in 2009 [22,23]. Quality control
strains, S. aureus ATCC® 25923, E. coli ATCC® 25922,
Pseudomonas aeruginosa ATCC® 27853 and Streptococ-
cus pneumoniae ATCC® 49619, were included with
each batch of isolates tested. The antimicrobial suscept-
ibility of Gram-positive bacteria was tested with penicil-
lin, ampicillin, cephalothin, clindamycin, erythromycin,
gentamycin, trimethoprim/sulfa and tetracycline. The
antimicrobial susceptibility of Gram-negative bacteria
was tested with ampicillin, gentamycin, trimethoprim/
sulfa, tetracycline, enrofloxacin, streptomycin, neomycin
and cefaperazone. The list of antibiotics in susceptibility
testing may vary, different veteriarians preferred differ-
ent set of antibiotics in order to find accurate treatment
after getting the laboratory test results.
The criteria for the interpretation of zone diameter
used in this study are described in Table 1.
Data analysis
The farm, herd size and year were recorded and cate-
gorised before statistical analysis. A logistic regression
model with a random herd effect for the control of clus-
tering was used for all of the analyses in this study.
Odds ratios (OR) with 95% confidence intervals (95%
CI) were calculated. Statistical significance was set at
p ≤ 0.005.
The influence of milk samples with mixed growth or
no bacterial growth on the occurrence of clinical or sub-
clinical mastitis was assessed. Potential interactions (no
growth or mixed growth × year) were assessed in the
logistic regression model. The effects of herd size and
year on the pathogens that caused clinical and subclini-
cal mastitis were analysed. These analyses were con-
ducted using Stata 10.2 [24].
Results
Isolation of mastitis pathogens
During the study period, 3058 clinical mastitis samples
from 190 farms and 5146 subclinical mastitis samples
from 274 farms were investigated (Table 2).
Positive results were found in 57% of the samples
(4680 out of 8204), and this proportion did not differ
according to year (p > 0.05). The proportion of bacterio-
logically negative samples was 22.3% and that of mixed
growth 20.6%. There was a significantly higher chance
(OR = 1.15, 95% CI = 1.01, 1.33, p = 0.042) of finding
bacteriologically negative samples in presence of subcli-
nical mastitis (n = 1317, 25.6%) in comparison with
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clinical mastitis (n = 554, 16.8%). The probability of
obtaining mixed growth from milk samples was also sig-
nificantly higher (OR = 2.2, 95% CI = 1.9, 2.6, p <
0.001) if subclinical mastitis was found. The distribution
of bacterial species isolated from samples from cows
with clinical and subclinical mastitis is shown in
Table 3. Among the bacteriologically positive (n = 2016)
clinical mastitis samples, Str. uberis was the bacterium
isolated most frequently (n = 371; 18.4% of the positive
samples), followed by E. coli (n = 321; 15.9%) and Str.
agalactiae (n = 293; 11.9%). S. aureus (n = 532; 20%)
and CNS (n = 411; 15.4%) were the bacteria isolated
most commonly from milk in cases of subclinical masti-
tis, followed by Corynebacterium spp. (n = 395; 14.8%).
The probability of isolating S. aureus from milk sam-
ples was significantly higher on farms that had fewer
than 30 cows, when compared with farms with more
than 100 cows (OR = 0.2, 95% CI = 0.11, 0.53, p <
0.005). Also, there was a significantly higher risk of diag-
nosing Str. agalactiae on farms with more than 600
cows (OR = 17.6, 95% CI = 1.2, 259.1, p = 0.034) com-
pared with smaller farms.
Antimicrobial susceptibility testing
The percentage of S. aureus isolates resistant to penicil-
lin and ampicillin was 61.4% and 59.5%, respectively. In
addition, CNS showed resistance to penicillin and ampi-
cillin (38.5% and 34.4%), but resistance to erythromycin
and lincomycin was also common (14.9% and 17.6%).
Six isolates (3.8%) of S. aureus and three isolates (3.6%)
of CNS were resistant to cephalothin (Table 4).
All streptococci (Table 5) were susceptible to penicil-
lin, ampicillin and cephalothin, except for one isolate
of Str. uberis. Of the 90 isolates of Str. dysgalactiae,
19.8% were classified with intermediate susceptibility
and 32.2% with resistance to tetracycline. Of a total of
151 isolates of Str. uberis, 7.3% with intermediate sus-
ceptibility and 14.3% with resistance to tetracycline
were recorded. Among the E. coli isolates (Table 6),
the highest percentage of isolates showing intermediate
susceptibility and resistance were observed with ampi-
cillin, neomycin, streptomycin and tetracycline. E. coli.
was 98.4% susceptible to enrofloxacin and 100% to
cefaperazone.
Discussion
The results of the present study were based on an analy-
sis of milk samples submitted to an Estonian National
Veterinary Laboratory over a three-year period. The
laboratory protocols did not change during the study
period. Of the samples investigated, 22.3% were bacter-
iologically negative. Several other studies have also
demonstrated bacteriologically negative findings in
17.7-26.5% cases of clinical mastitis [12,25] and as many
as 28.7-38.6% of subclinical mastitis [12,26], which is in
line with our results. The possible reasons for bacterio-
logically negative findings in milk samples could be the
presence of antibacterial substances in the milk that
lead to a decrease in the viability of bacteria in the cul-
ture [27], or failures in conventional culture compared
with identification of bacteria using the real-time poly-
merase chain reaction [28].
Table 1 Zone diameter intepretive criteria
Disc content in μg Staphylococcus spp. Streptococcus spp. Enterococcus spp. Enterobacteriaceae spp.
S I R S I R S I R S I R
Ampicillin 10 μg ≥ 29 - ≤28 ≥ 26 19-25 ≤18 ≥ 17 - ≤16 ≥ 17 15-16 ≤14
Penicillin 10 μg ≥ 29 - ≥ 29 ≥24 - - ≥15 - ≤14 - - -
Cephalothin 30 μg ≥ ≤ - - -
Cefaperazone 75 μg - - - - - - - - - ≥21 16-20 ≤15
Clindamycin 2 μg ≥ 21 15-20 ≥ 14 ≥19 16-18 ≤15 - - - - - -
Erythromycin 15 μg ≥ 23 14-22 ≥ 14 ≥21 16-20 ≤15 - - - - - -
Gentamycin 10 μg ≥ 12 13-14 ≥ 15 ≥12 13-14 15≤ ≥10 7-9 ≤6 ≥ 12 13-14 ≥ 15
Tetracycline 30 μg ≥ 19 15-18 ≥ 14 ≥23 19-22 ≤18 ≥19 15-18 ≤14 ≥ 19 15-18 ≥ 14
Enrofloxacin 5 μg ≥ 20 15-19 ≤14
Trimethoprim/sulfa 1,25/23,75 μg ≥ 16 11-15 ≥ 10 ≥16 11-15 ≤10 ≥16 11-15 ≤10 ≥ 16 11-15 ≥ 10
Table 2 Distribution of milk samples according to herd
size
Clinical mastitis Subclinical mastitis
Farm size
category
Farms % Samples % Farms % Samples %
1 (1-30
cows)
54 28.4 98 3.2 41 15 86 1.7
2 (31-99
cows)
35 18.4 149 4.9 51 18.6 268 5.2
3 (100-299
cows)
40 21.1 378 12.4 53 19.3 541 10.5
4 (300-599
cows)
44 23.2 1472 48.1 80 29.2 2426 47.1
5 (> 600
cows)
17 8.9 961 31.4 49 17.9 1825 35.5
Total 190 100 3058 100 274 100 5146 100
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In the present study, E. coli and Str. uberis were the
pathogens isolated most frequently from clinical masti-
tis, while S. aureus, CNS and Corynebacterium spp.
caused mainly subclinical mastitis. The same results
were shown in an Estonian study ten years ago, where
C. bovis (47.5%), S. aureus (21%) and CNS (15.8%) were
the pathogens isolated most commonly from cases of
subclinical mastitis [29]. The isolation rate of Str. aga-
lactiae was surprisingly high in our study.
We found a strong association between the isolation
of Str. agalactiae and very large-scale farms. In total,
there are 98000 dairy cows in Estonia and the mean
herd size is 88 cows [30]. Rapid changes in management
style (from tie-stalls to free-stalls) have occurred during
the last eight years, which may explain the coexistence
of environmental pathogens together with Str. agalac-
tiae. Although teat disinfection and dry cow therapy is a
common routine on Estonian dairy farms, proper eradi-
cation programmes for Str. agalactiae have not been
employed. In contrast, an increased probability of find-
ing S. aureus was correlated with farms with fewer than
30 cows. The average age of cows on small farms was
5.3 years, compared with 4.3 years on farms on which
more than 300 cows were kept [30]. The culling policy
may be different, and the owners of smaller farms may
keep (possibly chronically infected) cows in the herd for
a longer period of time.
The disc diffusion method for in vitro antimicrobial
susceptibility testing was used in this study. This techni-
que is the most widely used method for determination
of the susceptibility of animal pathogens, especially in
clinical work when it is necessary to determine the cor-
rect treatment. The primary disadvantage of using this
method when monitoring development of resistance is
that outcomes are reported on a qualitative basis (sensi-
tive, intermediate, or resistant), and subtle changes in
susceptibility may not be apparent. Therefore any com-
parison with studies that use other methods of suscept-
ibility testing is not acceptable [31].
Generally in our study, the in vitro antimicrobial resis-
tance of the isolates examined from samples of clinical
Table 3 Distribution of bacterial species isolated from clinical and subclinical mastitis samples in 2007-2009













S. aureus 11.7 11.7 11.7 19.2 22.8 16.6
CNS 4.8 7.1 8.5 16.1 13.6 17.4
CPS* 3.8 3.3 1.6 4.6 2.8 5.1
Str. agalactiae 9.0 11.3 14.7 13.6 9.0 10.7
Str. dysgalactiae 8.0 7.8 7.2 3.6 4.0 5.6
Str. uberis 16.1 21.8 17.1 10.2 12.3 12.9
Str. spp 3.2 3.3 1.9 1.2 2.0 2.7
Lactococcus lactis 10.9 3.9 5.7 8.9 8.2 3.9
E. coli 14.4 16.6 16.5 1.6 2.0 3.8
Klebsiella spp. 7.0 1.3 2.3 0.7 0.6 0.9
Enterococcus spp. 1.3 2.3 1.1 1.5 2.8 4.2
Corynebacterium spp. 2.2 2.6 5.0 16.5 17.3 8.5
A. pyogenes 2.2 3.8 3.6 0.1 0.6 0.6
Pseudomonas spp. 1 0.3 0.3 0 0 0.6
Proteus spp. 0.2 0 0.2 0.4 0.1 0.6
Yeast 2.3 2 1.6 1.5 1.6 5.6
Other 1.8 0.9 1 0.3 0.3 0.3
Total 100% 100% 100% 100% 100% 100%
* CPS: coagulase-positive staphylococci (other than S. aureus).
Table 4 Antimicrobial susceptibility of staphylococci
isolated from bovine clinical mastitis
S. aureus CNS












Ampicillin10 μg 173 40.5 - 59.5 91 61.5 - 38.5
Penicillin10 μg 174 38.6 - 61.4 93 65.5 - 34.4
Cephalothin 30 μg 160 96.2 - 3.8 84 96.4 - 3.6
Clindamycin 2 μg 169 81.9 0 18.1 91 82.4 0 17.6
Erythromycin15 μg 83 95.2 0 4.8 47 85.1 0 14.9
Tetracycline 30 μg 147 95.9 0 4.1 86 88.4 0 11.6
Trimethoprim/sulfa 1.25/
23.75 μg
162 96.6 0 3.4 76 97.4 0 2.6
Gentamycin 10 μg 146 93.2 0 6.8 69 98.6 0 1.4
* Propotion of susceptible (S), intermediate susceptibility (I) and resistant (R)
isolates.
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mastitis were high. Isolates of S. aureus had an alarming
level of resistance to penicillin (61.4%) and ampicillin
(59.5%), whereas CNS exhibited a lower degree of resis-
tance to penicillin and ampicillin (38.5%; 34.4%). The
reported percentages for penicillin resistant S. aureus in
cases of clinical mastitis, detected by the disc diffusion
method, are 50.4% and 35.4% in the USA [10,32], 63.3%
in Turkey [33] and 12% in Northern Germany [34]. In
addition, cephalothin resistance among staphylococci was
found in our study. Although reports of methicillin-
resistant staphylococci causing bovine mastitis are rare,
those samples found in our study need further investiga-
tion in order to prove or exclude the presence of the
mecA gene. In the present study, both staphylococci and
streptococci showed resistance to erythromycin and lin-
comycin, but the figures for resistance in annual reports
from some other countries show a low prevalence of lin-
comycin and erythromycin resistance in S. aureus and
CNS [13,14,35]. Given that S. aureus and CNS were the
pathogens isolated most frequently from cases of subcli-
nical mastitis, one possible explanation for resistance to
several antibiotics may be the collection and submission
to the laboratory of milk samples from chronic clinical
mastitis (which demonstrate poor treatment efficacy).
Therefore, random sampling strategies should be used to
provide a good evaluation of antimicrobial susceptibility.
The level of resistance of E. coli and Klebsiella spp. was
high against all tested antimicrobials, except cefaperazone
and enrofloxacin. Coliforms are often resistant to more
than one antimicrobial [36,37], and the number of multi-
resistant strains may influence the resistance figures. Coli-
form bacteria isolated from cases of mastitis may reflect
the general situation of resistance in the herd and can be
considered more as an indicator of the bacteria present
than an indicator of specific pathogens from the udder
[36]. All of the bacterial species investigated in the present
study showed resistance to tetracycline. A possible expla-
nation for this phenomenon could be that tetracycline has
been the class of antimicrobial most widely used for treat-
ment of several infections for many years. In addition, tet-
racycline has been found in multiresistant patterns with
penicillin and streptomycin [33,37].
Statistical data from the Estonian State Medical
Agency confirmed [19] that alltogether 209880 single
intramammary syringes for lactating cows and 205648
for dry cow therapy were sold in the year 2009. Ampicil-
lin and cloxacillin combinations, cephalosporins with
aminoglycosides, and lincomycin with neomycin were
the most common choices for the treatment of mastitis
in lactating cows. For example, 255 grams of intramam-
mary lincomycin (pure antimicrobial) and 44.2 grams of
intramammary cephalosporins per thousand dairy cows
were sold for the treatment of clinical mastitis in 2009
[19]. However, only 73.4 grams of penicillin G was used
per thousand dairy cows for intramammary treatment of
clinical mastitis. The use of broad-spectrum antibiotics
and antibiotic combinations may influence the resistance
of mastitis pathogens. In addition, bacteriological exami-
nation of milk samples before treatment of clinical mas-
titis is not a common practice in Estonia. According to
Table 5 Antimicrobial susceptibility of streptococci isolated from bovine clinical mastitis
Str. agalactiae Str. dysgalactiae Str. uberis
Disc content in μg n S*
(%)












Ampicillin 10 μg 162 100 - 0 111 100 0 0 265 99.6 0 0.4
Penicillin 10 μg 168 100 - 0 111 100 0 0 267 99.6 0 0.4
Cephalothin 30 μg 143 100 - 0 101 100 0 0 254 99.6 0 0.4
Clindamycin 2 μg 161 91.9 1.9 6.2 115 92.2 0 7.8 273 92 1.4 6.6
Erythromycin 15 μg 77 96.1 2.6 1.3 60 88.3 5 6.7 134 89.6 2.2 8.2
Tetracycline 30 μg 151 78.1 7.3 14.6 90 48.9 18.9 32.2 234 79.9 3.4 19.7
Trimethoprim/sulfa
1.25/23.75 μg
140 93.6 0 6.4 103 99 0 1 223 95.9 0.9 3.2
Gentamycin 10 μg 143 63.6 11.9 24.5 88 88.6 0 11.4 210 71.9 9.5 18.6
* Propotion of susceptible (S), intermediate susceptibility (I) and resistant (R) isolates.
Table 6 Antimicrobial susceptibility of E. coli and
Klebsiella spp. isolated from bovine clinical mastitis
E. coli Klebsiella spp.












Ampicillin 10 μg 201 68.7 7.0 24.3 39 15.4 7.7 76.9
Cefaperazone75 μg 137 100 0 0 32 100 0 0
Tetracycline 30 μg 184 77.8 8.7 13.5 39 79.6 10.2 10.2
Trimethoprim/sulfa 1.25/
23.75 μg
191 84.3 3.7 12.0 40 97.5 0 2.5
Gentamycin 10 μg 161 94.3 2.5 2.2 40 95.0 0 5.0
Streptomycin 300
μg
154 78.6 5.8 15.6 37 73.0 8.1 18.9
Neomycin 30 μg 155 72.9 20.6 6.5 37 83.8 13.5 2.7
Enrofloxacin 5 μg 185 98.4 0 1.6 37 100 0 0
* Proportion of susceptible (S), intermediate susceptibility (I) and resistant (R)
isolates.
Kalmus et al. Acta Veterinaria Scandinavica 2011, 53:4
http://www.actavetscand.com/content/53/1/4
Page 5 of 7
the available data in Sweden, intramammary and intra-
muscular penicillin G [38] are used in over 80% of cases
for treatment of clinical mastitis, but the prevalence of
resistance of S. aureus to penicillins is only 7.1% [36]. In
Finland, penicillin G and some broad-spectrum b-lactam
antibiotics are used in the treatment of clinical mastitis,
but the prevalence of resistance in S. aureus is only 13%
[39]. Bacteriological examination before treatment is
common in both countries.
Considering these results, we can assume that the
main reason for the occurrence of a high number of
resistant strains in Estonian herds is the wide use of
broad-spectrum antimicrobials and the long-term pre-
sence of infected cows in herds.
Conclusion
This study showed that the main pathogens that caused
clinical mastitis were Str. uberis and E. coli. Subclinical
mastitis was caused mainly by S. aureus and CNS.
A relatively high number of isolates of Str. agalactiae
were cultured from both types of case. The number of
S. aureus and Str. agalactiae isolates depended on herd
size. Among the bacteria investigated, the prevalence of
antimicrobial resistance was extremely high, especially
penicillin resistance in S. aureus and CNS.
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